The individual reports in the supplement were derived from the planning teleconference of the same title as noted above. Dr. Biederman's article provided an introduction and overview to other articles that followed his. Dr. Biederman fully disclosed that he has received research support from Cephalon and that he also serves on the company's speaker's bureau and advisory board. 3 In his article, Dr. Biederman stated:
The pharmacologic profile and structure of modafinil are notably different from those of stimulants and other agents used to treat ADHD, and modafinil may reduce the core symptoms of ADHD via the same mechanism by which it improves wakefulness-selective activation of the cortex without generalized effects on the central nervous system. This mechanism results in reduced abuse potential and less likelihood of jitteriness, anxiety, or excess locomotor activity than traditional stimulants. 1(p4) That statement, however, is contradicted by 2 federal drug enforcement agencies. The U.S. Food and Drug Administration (FDA)-approved product label for modafinil (Provigil), in the section "Abuse Potential and Dependence," states:
In addition to its wakefulness-promoting effect and increased locomotor activity in animals, in humans, PROVIGIL produces psychoactive and euphoric effects, alterations in mood, perception, thinking and feelings typical of other CNS [central nervous system] stimulants. 4(p1005) Furthermore, the product label continues:
The abuse potential of modafinil (200, 400, and 800 mg) was assessed relative to methylphenidate (45 and 90 mg) in an inpatient study in individuals experienced with drugs of abuse. Results from this clinical study demonstrated that modafinil produced psychoactive and euphoric effects and feelings consistent with other scheduled CNS stimulants (methylphenidate). 4(pp1005-1006) Additionally, the Drug and Chemical Evaluation Section of the Drug Enforcement Administration (DEA), Office of Diversion Control, evaluation previously stated:
Modafinil is a central nervous system stimulant that is being considered for approval by the FDA, under the trade name Provigil ® . Modafinil is being considered for marketing as a prescription drug product for the treatment of excessive daytime sleepiness associated with narcolepsy. Modafinil produces many of the same pharmacological effects and adverse reactions as classic psychomotor stimulants . . . 5 Our concern with Dr. Biederman's commentary is that it appears to seriously misrepresent modafinil's neuropharmacologic characteristics, contradicting the science-based evaluation of the data by the U.S. FDA and DEA. Dr. Biederman may have misrepresented modafinil's pharmacologic (stimulant) properties and minimized modafinil's abuse potential-as described in the authoritative FDA-approved product label. Dr. Biederman's misrepresentation of the serious risks posed by this drug, whose target population is children with ADHD, requires reexamination and correction.
Of note, if Cephalon, Inc., were to directly mischaracterize modafinil's pharmacocharacteristics-as Dr. Biederman hasthey could be prosecuted under federal law. 
Dr. Klotz is on the speaker's bureau of Pfizer Inc and has been a speaker for and consultant to

Dr. Biederman Replies
Sir: The background research to support the claims of Drs. Kruszewski and Klotz begins and ends with the manufacturer's package insert. However, the manufacturer's package insert is neither a standard of care nor the most comprehensive and upto-date review of the preclinical or clinical science about a molecule. Were that so, new knowledge or findings would never be able to be conveyed to the field until the company or the U.S. Food and Drug Administration (FDA) determined to alter the manufacturer's package insert. Further, the labeling reflects information provided to the FDA at the time of submission of the compound and not necessarily the universe of scientific information available.
A search of the scientific literature indicates that there have been numerous studies conducted with modafinil which report that modafinil blunts cocaine-induced euphoria, 1-4 does not produce amphetamine-like effects, 5, 6 and is indistinguishable from the subjective stimulant effects of caffeine. 7 Additionally, all of the evidence from the literature on the abuse liability of modafinil suggests a much lower potential for abuse and dependency than for amphetamine-like stimulants. 8 As an independent clinician-researcher and not the agent of the manufacturer, I am compelled to base my teaching on all the information and knowledge available to me.
The authors' primary concern appears to be what they believe are the "serious" consequences of abuse and addiction associated with modafinil (hence, "mischaracterization"). However, both the FDA and the Drug Enforcement Administration (DEA) documents are in complete agreement with my very clear position that modafinil has reduced abuse potential and less likelihood for jitteriness, anxiety, and locomotor activity than traditional stimulants. In fact, the key supporting evidence could be taken directly from those documents: J Clin Psychiatry 68:6, June 2007
• First and perhaps most importantly, the definitions of Schedule II and Schedule IV clearly make my statements consistent with DEA documentation and their own determination about the relative potential abuse liability for modafinil compared to traditional stimulants. Traditional stimulants are classified in Schedule II ("the drug or other substance has a high potential for abuse"), while modafinil is in the less-restricted Schedule IV ("the drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule [I, II, and] III"). 9 • The authors mischaracterize the evaluation of the Drug and Chemical Evaluation Section of the DEA, Office of Diversion Control, 10 by including a partial quotation in their letter. The full quotation reads as follows:
Modafinil is a central nervous system stimulant that is being considered for approval by the FDA, under the trade name Provigil ® . Modafinil is being considered for marketing as a prescription drug product for the treatment of excessive daytime sleepiness associated with narcolepsy. Modafinil produces many of the same pharmacological effects and adverse reactions as classic psychomotor stimulants, but appears to have chemical properties that may limit its abuse (i.e., not water soluble, decomposes in heat). DEA is unaware of any reports of modafinil abuse. 10 [Italics added to highlight omitted text.]
• The FDA labels for methylphenidate and amphetamines include a black box warning for a high potential for abuse and dependence, and modafinil's label does not. • Methylphenidate and amphetamines have contraindications for agitated states and patients with a history of drug abuse in their product information [11] [12] [13] [14] ; modafinil has no such contraindication. • Methylphenidate is contraindicated in patients with marked anxiety, tension, and agitation [12] [13] [14] ; modafinil has no such contraindications. • Finally, as stated in my remarks, the pharmacologic profile and structure of modafinil are notably different from those of stimulants and other agents used to treat attention-deficit/hyperactivity disorder (ADHD). As stated, modafinil is a chemically unique molecule unrelated to stimulants or other treatments for ADHD.
The letter by Drs. Kruszewski and Klotz seriously misrepresents the facts, shows ignorance about the neuropharmacologic characteristics of modafinil, and demonstrates a failure to understand the clinical significance of alternative treatments for ADHD. The accusation that my statement may have misrepresented modafinil's pharmacologic (stimulant) properties and minimized modafinil's abuse potential is baseless. 
Dr. Biederman receives or has received research support from, is or has been a speaker for, or is or has been on the advisory board for
Aripiprazole Augmentation of Clomipramine-Refractory Obsessive-Compulsive Disorder
Sir: Antipsychotic augmentation strategy is relevant in obsessive-compulsive disorder (OCD), as half of patients fail to respond to an initial adequate trial of serotonin reuptake inhibitors. 1 Aripiprazole is an antipsychotic drug that acts as a partial agonist at dopamine D 2 and serotonin 5-HT 1A receptors. The drug is also a serotonin 5-HT 2A receptor antagonist that might be of therapeutic value in OCD, as suggested by an open-label aripiprazole monotherapy study. 2 Unlike for other atypical antipsychotics, no aripiprazole augmentation study or case series in refractory OCD has yet been reported. We report the first case of clomipraminerefractory OCD that responded to the addition of aripiprazole.
Case report. Mr. A, a 37-year-old white man, was referred to our clinic in January 2006 for worsening of OCD, which was diagnosed 16 years previously. Mr. A was never in a psychotic state and always had good insight into his mental problem. He received behavior therapy and several selective serotonin reuptake inhibitors (SSRIs), with modest results due to a lack of good compliance. He fulfilled DSM-IV-TR criteria for OCD J Clin Psychiatry 68:6, June 2007 and major depressive disorder, recurrent, severe episode, with partial remission between episodes. He scored 32 on the Yale-Brown Obsessive Compulsive scale (YBOCS) 3 and 26 on the Hamilton Rating Scale for Depression 17-item (HAM-D 17-item). 4 Clomipramine was progressively initiated over the course of 2 weeks with clonazepam (1-3 mg/day at the patient's discretion) and maintained at a fixed dose of 225 mg/day during 8 weeks with adequate plasmatic dosage. Despite a meaningful clinical response of the patient's depression (HAM-D 17-item score = 12), Mr. A's YBOCS score was stable at 30 to 32. Aripiprazole (fixed dose of 15 mg/day) was then added to clomipramine (225 mg/day) for 16 weeks. Mean YBOCS scores and percentage reductions in score from baseline with the aripiprazole augmentation strategy were as follows: week 1, 27 (10.0%); week 2, 21 (30.0%); week 4, 16 (46.7%); week 6, 16 (46.7%).
Because of this meaningful clinical response (≥ 35% improvement in baseline YBOCS total score), Mr. A was able to leave our clinic. No change in plasmatic clomipramine dosage was observed. This response was maintained at week 10 (YBOCS score = 16), and Mr. A was in remission (YBOCS score = 15) at week 16. The 16-week augmentation treatment was well tolerated, and optional clonazepam treatment was stopped after 3 weeks. During the aripiprazole treatment, no change in the severity of depression (stability of HAM-D 17-item scores) was reported. At week 16, Mr. A fulfilled the DSM-IV-TR criteria for partial remission of major depressive disorder with a HAM-D 17-item score of 11.
Although we cannot rule out a delayed effect of clomipramine after 8 weeks, the addition of aripiprazole to ongoing clomipramine appears to be a promising strategy for clomipramine-refractory OCD patients. The beneficial effect of aripiprazole augmentation, irrespective of the course of depression, may be attributable to a direct pharmacodynamic action. Nevertheless, further larger controlled studies are required to evaluate the therapeutic potential of aripiprazole augmentation in patients suffering from SSRI-refractory OCD with or without comorbid major depressive disorder.
Lack of Mania Prophylaxis Associated With Lamotrigine Monotherapy in Manic-Predominant Bipolar I Disorder
Sir: Unlike all other mood-stabilizing drugs, lamotrigine does not have an indication for acute mania. The maintenance indication for lamotrigine is based on two 18-month studies evaluating time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in bipolar I patients treated for acute mood episodes with standard therapy. Only when these 2 studies were analyzed together (a priori determined to increase statistical power) was the superiority of lamotrigine over placebo in delaying the time to intervention for a manic episode evident. 1 As the following case reports highlight, lamotrigine may have limitations as monotherapy for mania prophylaxis in DSM-IV manic-predominant bipolar I disorder. Case 1. Ms. A, a 23-year-old student, was treated with olanzapine 10 mg and lamotrigine 250 mg daily for her first manic episode in April 2005. On this regimen, she became euthymic, with no evidence of postmanic depressive symptoms. Due to weight gain and sedation, olanzapine treatment was discontinued in January 2006. On lamotrigine monotherapy, Ms. A showed no evidence of depressive relapse or recurrence.
One week after the 2006 spring equinox, her parents noted a return of decreased sleep, racing thoughts, pressured speech, emotional lability, and increased goal-directed activities. This episode confirmed a spring equinox vulnerability and manicpredominant bipolar I disorder. Lamotrigine was augmented with olanzapine 7.5 mg daily, with symptom resolution. Case 2. Mr. B, a 22-year-old student, was hospitalized and treated with divalproex 2000 mg daily for his first manic episode in August 2005. One month after discharge, he discontinued divalproex treatment, believing his persistent depressive symptoms were drug related. Observing no improvement, his psychiatrist started lamotrigine treatment. At a dose of 200 mg daily, he was euthymic, with no evidence of depressive relapse or recurrence.
Mr. B was brought to the emergency room in April 2006 for grandiosity, pressured speech, racing thoughts, insomnia, and impulsive high-risk behaviors. Although not as clearly demarcated as Ms. A's, Mr. B's second episode led to a high suspicion that his manic-predominant bipolar I disorder had a spring/ summer seasonal pattern. He was restabilized on treatment with divalproex 2000 mg and lamotrigine 100 mg daily.
Despite pooled data supporting mania prophylaxis, these cases suggest that lamotrigine monotherapy was inadequate for mania prophylaxis in manic-predominant bipolar I disorder. Conversely, the data for lamotrigine, as monotherapy 2,3 and adjunctive to lithium maintenance therapy, 4 suggest acute antidepressant effect; the data are much more solid evidence for its efficacy as a maintenance treatment in preventing depression. 5 Furthermore, the reasons for choosing lamotrigine for these patients were common ones (i.e., weight gain associated with olanzapine and postmanic depressive symptoms ineffectively treated with divalproex).
Clinical practice has evolved into identifying "above baseline" (mania, mixed states, hypomania) and "below baseline" (depression) treatments. 6 In addition, assessing prior episode burden or pole-predominance may help clarify when, for example, lamotrigine could be utilized as a primary mood stabilizer.
These cases also highlight several areas of further research. First, the merits of long-term combination treatment (i.e., lamo-J Clin Psychiatry 68:6, June 2007 trigine with an atypical antipsychotic or divalproex) versus single-agent therapy should be evaluated for ongoing mood stability and tolerability; this is a common community practice with little controlled literature to guide clinicians. Second, when seasonal vulnerability for mania can be established and if lamotrigine is the treatment of choice in a bipolar patient, adjunctive short-term augmentation with an "above baseline" treatment should be evaluated for mania prophylaxis.
Dr. Stahl Replies
Sir: When the mechanism of action of psychotropic drugs can successfully explain their clinical actions, this generally means that the best of the science of receptor pharmacology has been thoughtfully combined with the best of the art of clinical observation. Mr. Shayegan and I reviewed the receptor binding properties of ziprasidone 1 and all atypical antipsychotics 2 and provided hypotheses about which receptor binding actions were common to all atypical antipsychotics, which were unique for some agents and not others, and, finally, which receptor binding properties could feasibly be related to efficacy versus side effects of the various drugs in this class. Brophy has used this approach in an attempt to explain his clinical observations of motor restlessness with ziprasidone and hypothesizes that the serotonin-1B (5-HT 1B ) actions of ziprasidone, but not the 5-HT 2C actions that we propose to account for behavioral activation of ziprasidone, may account for these observations.
Our hypothesis is that 5-HT 2C antagonist properties of ziprasidone may account for its activating behavioral side effects (such as agitation, anxiety, hypomania, and panic) at low doses. 1,2 These adverse experiences generally occur without concomitant antipsychotic therapeutic effects at low doses, and we explain this as due to the more potent actions of ziprasidone at 5-HT 2C receptors than at dopamine D 2 receptors. 1, 2 We point out that such actions would be expected to disinhibit dopamine and norepinephrine release in the cortex without adequate simultaneous blockade of D 2 receptors 1,2 and that the same pharmacologic profile has been described for fluoxetine, an agent that can also cause similar activating behavioral side effects. [3] [4] [5] [6] [7] We further propose that raising the dose of ziprasidone recruits additional D 2 receptor blockade in the presence of already saturated 5-HT 2C receptors, resulting in loss of behavioral activation and production of antipsychotic effects, and therefore, to avoid behavioral activation and in order to get robust antipsychotic effects, we advise against utilizing low doses of ziprasidone. 1, 2 We believe that this pharmacologic explanation for the induction of activating behavioral side effects of low-dose ziprasidone remains valid and that it may also explain the motor restlessness observed with ziprasidone and why increasing the dose of ziprasidone (perhaps with short-term use of benzodiazepines) may be the appropriate clinical response when motor restlessness is observed with ziprasidone. However, Brophy makes several points to argue that this hypothesis does not adequately explain restlessness associated with ziprasidone: fluoxetine is an agonist and not an antagonist at 5-HT 2C receptors; ziprasidone is an inverse agonist rather than an antagonist at 5-HT 2C receptors; ziprasidone's actions as a partial agonist at 5-HT 1B receptors explain its motor activation since this fits with animal data on hyperlocomotor behavior; and, finally, and most importantly, raising the dose of ziprasidone from 40 mg b.i.d. to 60 mg b.i.d. does not improve motor activation.
We respond here to each of these in turn. Although there is some evidence that fluoxetine may be an agonist at 5-HT 2C receptors, this is countered by others that suggest it may be an antagonist. [3] [4] [5] [6] It may matter little clinically which is true, since both agonists and antagonists of 5-HT 2C receptors rapidly down-regulate these receptors, [3] [4] [5] [6] and thus multiple dose effects of both may be similar. We agree that ziprasidone may be an inverse agonist rather than an antagonist at 5-HT 2C receptors in some assay systems, but this is perhaps a distinction without a clinical difference, since both silent antagonists and inverse agonists antagonize 5-HT actions at 5-HT 2C receptors and inverse agonism is defined for receptor systems with high densi-ties of receptors that have detectable constitutive activity, which may not apply in the cerebral cortex, where 5-HT 2C receptor density is low. Although some evidence is consistent with partial agonist actions of ziprasidone at 5-HT 1B receptors (previously called 5-HT 1D receptors in humans and so labeled in references 1 and 2), other data suggest that it may be an antagonist, which would not be consistent with the idea that ziprasidone causes restlessness by stimulating 5-HT 1B receptors. 7 To the extent that ziprasidone does stimulate 5-HT 1B receptors, as these receptors are located on serotonergic axon terminals, this would prevent the release of serotonin onto 5-HT 2C receptors (and others), creating a net but indirect 5-HT 2C antagonist action, consistent with our original hypothesis. Finally, clinical observations of what happens with dosage increase with ziprasidone in patients with motor restlessness are variable, with some patients failing to improve, especially after small dosage increases as observed by Brophy, but with a growing consensus also suggesting that there is not only greater efficacy but overall paradoxically lower motor side effects of ziprasidone at higher doses than lower doses (reference 8 and Anthony Loebel, M.D., data on file, Pfizer Inc, 2002-2005), particularly when comparing 160 mg daily with lower doses.
The bottom line here is, What does a clinician do with this receptor binding information to become informed about what starting dose to use for ziprasidone and what dosing adjustments to make if behavioral or motor restlessness emerges, especially at low doses? One never says "always" in clinical psychopharmacology, since some patients do indeed seem to have more rather than less tolerability to higher doses of ziprasidone, including motor restlessness. Thus, we agree with Brophy that activating motor symptoms may not always improve with a dose increase, perhaps because in some patients the 5-HT 2C receptor mechanism does not explain their side effects. However, we stand by our original recommendation on the basis of both receptor profile 1,2 and emerging clinical experience (reference 8 and Anthony Loebel, M.D., data on file, Pfizer Inc, 2002-2005) that ziprasidone's tolerability and efficacy may be enhanced by not starting the dose too low and, when there are activating side effects, raising the dose. When this intervention reduces side effects as suggested by recent data analyses and clinical experience (reference 8 and Anthony Loebel, M.D., data on file, Pfizer Inc, 2002-2005), this otherwise counterintuitive result is nevertheless consistent with the hypothesis that increased doses recruit D 2 antagonism to counter the activation caused by 5-HT 2C antagonism.
The best merger of art and science may be to start ziprasidone at mid-dose range, 80 mg a day, either as 40 mg b.i.d. or 80 mg once at night, increasing the next day to 160 mg a day, either as 80 mg b.i.d. or 160 mg at night, always with food, and even in the face of behavioral or motor activating side effects. One can always use more time at a given dose or the addition of a benzodiazepine when experiencing side effects during initiation or dosing adjustment of ziprasidone as well. The idea is to use receptor pharmacology to guide clinical dosing of various agents and then to tailor specific dosing for individual patients on the basis of good clinical observation. J Clin Psychiatry 68:6, June 2007 on obesity and binge-eating behavior are limited from these clinical populations. Our research group previously reported data on weight in large samples of boys and girls ascertained from psychiatric and pediatric settings, as part of an analysis of their growth characteristics. 1, 2 These studies failed to identify meaningful differences in body mass index between youth with and without ADHD. More work will be needed to further examine these issues in adult samples.
We appreciate Cortese and colleagues' suggestion that ADHD might contribute to dysregulation of eating behavior or correlate in some way with obesity, and we welcome further investigation into the relationship between ADHD and these as well as other health risk factors.
